drugset / Trial / NCT00150553

Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder

NCT00150553

Phase 3 Completed 102 enrolled Validus Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of SPD417 in treating bipolar manic symptoms, when given once daily in the evening vs. twice daily.

Timeline

Start
2005-01
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule

Indications